Yunus Gürbüz, Aysel Kocagül-Çelikbaş, Nefise Öztoprak, Bilgehan Aygen, Ayşe Batırel, Arif Doğan Habiloğlu, Nazlım Aktuğ-Demir, Sabahat Çeken, Neşe Demirtürk, Mehmet Reşat Ceylan, Şengül Üçer, Faruk Karakeçili, Sevil Alkan, Nevin İnce, Anıl Akça, Veli Günay, Duru Mustanoğlu-Özatağ, Güle Çınar, Sami Kınıklı, Orhan Yıldız, Petek Şarlak-Konya, Şua Sümer, Dilek Yekenkurul, Mehmet Çelik, Umut Devrim Binay, Zahide Aşık-Otman
{"title":"The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data.","authors":"Yunus Gürbüz, Aysel Kocagül-Çelikbaş, Nefise Öztoprak, Bilgehan Aygen, Ayşe Batırel, Arif Doğan Habiloğlu, Nazlım Aktuğ-Demir, Sabahat Çeken, Neşe Demirtürk, Mehmet Reşat Ceylan, Şengül Üçer, Faruk Karakeçili, Sevil Alkan, Nevin İnce, Anıl Akça, Veli Günay, Duru Mustanoğlu-Özatağ, Güle Çınar, Sami Kınıklı, Orhan Yıldız, Petek Şarlak-Konya, Şua Sümer, Dilek Yekenkurul, Mehmet Çelik, Umut Devrim Binay, Zahide Aşık-Otman","doi":"10.36519/idcm.2024.344","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to demonstrate the real-life efficacy and safety of glecaprevir /pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients.</p><p><strong>Materials and methods: </strong>The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-naïve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment.</p><p><strong>Results: </strong>Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events.</p><p><strong>Conclusion: </strong>Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"6 3","pages":"216-224"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465448/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases & clinical microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/idcm.2024.344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to demonstrate the real-life efficacy and safety of glecaprevir /pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients.
Materials and methods: The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-naïve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment.
Results: Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events.
Conclusion: Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
